If you not change browser settings, you agree to it. Learn more
points
Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. For these reasons, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the “classic” clinical specialties. Finally, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.
With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.
This 14th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where opinion leaders and attendees will exchange experiences and share the most exiting advances.
In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 14th AIBCC will award the 8th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year. For the first time, we also welcome the presentation of posters from the participants and the bets poster will be awarded during the Award Cerimony.
We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.
Physicians specialized in anatomical pathology, gynaecology and obstetrics, oncology, radiology, radiotherapy. Biologists and nurses.
It won’t be possible give credits to physicians specialized in different fields.
The official language of the Meeting is English. No simultaneous translation will be provided.
The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.
Some fellowship (for under 40) will be awarded which will include registration and 3 Hotel nights. Those interested should send the registration form together with a short CV and a motivation letter within July 1st.
The organizing secretariat will confirm the award of the fellowship within July 20th and it will proceed with the organization of logistics.
Free admission is available for 3 persons “under 35”. Registration forms will be accepted on a first-come, first-served basis unitil spaces are filled. The Organization Secretariat will confirm the registration by email.
Based on Italian regulations, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-228175): 11,2 CME points.
The credit certification is subject to:
We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.
Participants can send one or more abstracts.
The form should be filled out by following specific guidelines:
Abstracts will be selected by the Scientific Committee and will be shown during the poster session on September 22nd from 8 am. Poster size: 70 (wide) x 100 (high).
People sending the selected abstracts will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement € 200,00 for Italian participants and € 300,00 for European participants).
Abstracts should be sent within July 1st. A confirmation will be sent by email within July 20th.
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padua (I)
The University of Texas - MD Anderson Cancer Center
Houston (USA)
Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)
German Breast Group
Department of Medicine and Research
University of Frankfurt (D)
Medical Oncology Service
Hospital Universitario Gregorio Marañon
Madrid (E)
Europa Donna Italia
Milan (I)
Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)
President of ESTRO; President-Elect of ECCO
Department of Radiation Oncology
Institut Curie
Paris (F)
Institute of Oncology (VHIO)
Vall d’Hebron- Institute of Oncology
Barcellona (E)
Multidisciplinary Oncology Institute
Clinique De Genolier
Genolier (CH)
Medical Oncology Unit AULS 8
Berica Distretto Ovest
Arzignano (I)
Medical Oncology Unit 1
IRCCS Istituto Nazionale Tumori
Milan (I)
Medical Oncologi B
Oncology Center
Aviano (I)
Medical Oncology Unit
G.B. Rossi Hospital
Verona (I)
Radiology Unit
Istituto Oncologico Veneto IRCCS
University of Padua (I)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Gynaecology Unit
Praxisklinik am Rosengarten
Mannheim (D)
Department of Radiation Oncology
Instituto Madrileño de Oncología (Grupo IMO)
Murcia (E)
Unit of Molecular Senology
European Institute of Oncology
Milan (I)
Obstetrics & Gynecology Unit
S. Chiara Hospital
Pisa (I)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Department of Surgery
Medical University
Wien (A)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Reference Center Mammographie
Munchen (D)
MD Anderson Cancer Center Orlando
Comprehensive Breast Program
Orlando (F)
Pathology Unit
Candiolo Cancer Institute IRCCS
Candiolo (I)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Breast Surgery
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Medical Oncology
“S. Anna” Hospital
Ferrara, Cona (I)
Clinical nutrition and dietetics
Istituto Oncologico Veneto
Padova (I)
General Pathology and Cytopatology Unit
Department of Medicine-DIMED
University of Padua (I)
Medical Oncology
Oncology Center
Aviano (I)
Cancer Immunotherapy Center
Institut Curie
Paris (F)
UCSF Carol Franc Buck Breast Care Center
Breast Oncology Clinical Trials Program
San Francisco (USA)
Breast Surgery
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Centre for Experimental Cancer Medicine Bart Cancer
Institute Queen Mary University
London (UK)
Gruppenleiter
Inselspital
Bern (E)
Washington Cancer Institute
Washington (USA)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)
Department of Pathology
European Institute of Oncology
University of Milan (I)
Familial Cancer Clinic (Unità tumori ereditari)
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
Padova
8.30
Registration
9.15
Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi
Chairmen: Francesca Caumo, Stefania Zovato
9.30
Population screening vs risk-adapted surveillance
Sylvia Heywang – Kobrunner
9.50
Pharmacological prevention: how and whom?
Elefterios Mamounas
10.10
A look into the future: multigene panels
Gabriel N. Hortobagyi
10.30
Q&A
10.45
Coffee break
Chairmen: Jacek Jassem, Gabriel N. Hortobagyi
11.15
Evolution in surgical management of the axilla
Viviana E. Galimberti
11.45
Do margins still matter for in situ and invasive lesions?
Elefterios Mamounas
12.15
Radiation therapy: what is the real target to aim at
Philip Poortmans
12.45
Q&A
13.00
Lunch
14.00
Multidisciplinary Tumor Board 1 – Locoregional treatment
Chairmen: Pier Franco Conte, Stefania Migliuolo
15.00
Diet: myths and facts
Mariateresa Nardi
15.20
Complementary therapies
Claudia Bozza
15.40
Scalp cooling
Laura Marchioro
16.00
Q&A
10.20
Coffee break
Chairmen: Hesham Ahmed Gaballah Elghazaly, Valentina Guarneri
16.40
Gynecologic
Marco Gambacciani
17.00
Cardiovascular and metabolic
Thomas Suter
17.20
Bone health
Ingo Diel
17.40
Q&A
18.00
Adjourn
Chairmen: Enrico Orvieto, Peter Schmid
9.00
HER2 testing guidelines: new ASCO/CAP 2018
Giuseppe Viale
9.20
Molecular stratification of HER2+ and TNBC
Aleix Prat
9.40
Lobular breast cancer: a separate entity?
Caterina Marchiò
10.00
Q&A
10.20
Coffee Break
Chairmen: Sybille Loibl, Aleix Prat
10.50
Insights in resistance to CDK4/6 inhibitors
Stephen Johnston
11.10
Targeting the immune system: hopes and hypes
Peter Schmid
11.30
Combining radiotherapy and immunotherapy
Emanuela Romano
11.50
PARPi and other promising agents
Gabriel N. Hortobagyi
12.10
Q&A
12.30
Lunch
Chairmen: Stephen Johnston, Gabriel N. Hortobagyi
14.00
Extended adjuvant endocrine therapy: why? for whom? with what?
Michael Gnant
14.30
Risk adapted adjuvant treatment for HER2+ disease
Pier Franco Conte
15.00
Most promising ongoing trials in early disease
Hope Rugo
15.30
Q&A
16.00
Multidisciplinary Tumor Board 2 – Early Breast Cancer: challenging cases for pathologists and clinicians
17.00
Adjourn
17.30
Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2018 and best poster award
17.45
Lecture of the Awardee
18.15
Cocktail
19.30
Adjourn
Chairman: Pier Franco Conte, Stephen Johnston
9.00
New therapeutic algorithms
HR+ disease - Sibylle Loibl
HER2+ disease - Valentina Guarneri
TN disease - Miguel Martin
10.30
Q&A
10.40
Coffee break
11.00
Do elderly patients require special management?
Matti Aapro
11.20
Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer
Chairman: Sandra Swain
Panelists: Giulia Valeria Bianchi, Jacek Jassem, Philip Poortmans, Hope Rugo
12.45
Adjourn and final evaluation questionnaire
Tax free.
They include the conference bag and all coffee breaks and lunches. They do not include Hotel accomodation, dinners and travel expenses.
Click on the following button to open the on line registration form (in italian language):
…or click on the following button for the application form in english (PDF document): download it, print it, fill it out manually and send it via fax to number +39.051.0569.162, within august 25th, 2018 (instructions inside):